CapsoVision, Inc. (CV)
| Market Cap | 354.93M |
| Revenue (ttm) | 13.55M +15.3% |
| Net Income | -25.32M |
| EPS | -1.03 |
| Shares Out | 49.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,680 |
| Open | 7.11 |
| Previous Close | 7.19 |
| Day's Range | 7.08 - 7.29 |
| 52-Week Range | 3.43 - 15.37 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 10.00 (+40.45%) |
| Earnings Date | May 14, 2026 |
About CV
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as a... [Read more]
Financial Performance
In 2025, CapsoVision's revenue was $13.55 million, an increase of 15.29% compared to the previous year's $11.76 million. Losses were -$25.32 million, 27.2% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for CV stock is "Buy" and the 12-month stock price target is $10.0.
News
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solution...
CapsoVision files to sell 2.87M shares of common stock for holders
16:39 EDT CapsoVision (CV) files to sell 2.87M shares of common stock for holders
CapsoVision price target lowered to $10 from $14 at Benchmark
Benchmark analyst Bruce Jackson lowered the firm’s price target on CapsoVision (CV) to $10 from $14 and keeps a Speculative Buy rating on the shares after the company reported Q4
CapsoVision Earnings Call Transcript: Q4 2025
Revenue grew 15% year-over-year in 2025, driven by CapsoCam Plus adoption and new account growth. AI-enabled product pipeline advanced, with pivotal studies and regulatory submissions on track. Balance sheet strengthened by $14 million equity raise.
CapsoVision price target raised to $11 from $7 at Roth Capital
Roth Capital raised the firm’s price target on CapsoVision (CV) to $11 from $7 and keeps a Buy rating on the shares after its Q4 pre-announcement and the closing of
CapsoVision Transcript: The 38th Annual Roth Conference
CapsoVision highlighted its AI-powered capsule endoscopy platform, targeting major GI markets with a robust pipeline for colon, pancreas, esophagus, and stomach imaging. Strategic partnerships and recent financing support expansion and R&D through 2026.
CapsoVision jumps over 20% after announcing preliminary Q4 revenue
CapsoVision (CV) on Friday announced the closing of a $14M private placement in public equity financing pursuant to a securities purchase agreement entered into by the company with selected accredited
CapsoVision price target raised to $11 from $7 at Roth Capital
Roth Capital raised the firm’s price target on CapsoVision (CV) to $11 from $7 and keeps a Buy rating on the shares after the company announced preliminary sales for Q4
CapsoVision announces $14M private placement financing
CapsoVision (CV) “announced the closing of a $14 million private placement in public equity financing pursuant to a securities purchase agreement entered into by the company with selected accredited i...
CapsoVision Announces $14 Million Private Placement Financing
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results
CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solution...
CapsoVision price target raised to $14 from $5 at Benchmark
Benchmark raised the firm’s price target on CapsoVision (CV) to $14 from $5 and keeps a Speculative Buy rating on the shares after the company announced that it submitted a
CapsoVision submits 510(k) application to FDA for CapsoCam Plus
CapsoVision (CV) announced submission of its 510(k) application to the FDA for its proprietary AI-assisted module for CapsoCam Plus. The company intends for U.S. commercialization activities to commen...
CapsoVision Inc trading halted, volatility trading pause
15:55 EST CapsoVision (CV) Inc trading halted, volatility trading pause
CapsoVision Inc trading resumes
16:00 EST CapsoVision (CV) Inc trading resumes
CapsoVision Inc trading resumes
11:36 EST CapsoVision (CV) Inc trading resumes
CapsoVision Inc trading halted, volatility trading pause
11:26 EST CapsoVision (CV) Inc trading halted, volatility trading pause
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference
SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions...
CapsoVision Earnings Call Transcript: Q3 2025
Q3 2025 saw 19% revenue growth, strong adoption of CapsoCam Plus, and pipeline expansion with FDA submissions for AI and pancreatic cancer screening. IPO proceeds boosted cash reserves, while a one-time R&D charge impacted net loss.
CapsoVision reports Q3 EPS (17c) vs ($2.79) last year
Reports Q3 revenue $3.5M vs $2.967M last year. “We delivered a strong third quarter, driven by robust uptake of our CapsoCam Plus endoscopy capsule for small-bowel and growing physician-and-clinic eng...
CapsoVision submits CapsoCam breakthrough device designation application to FDA
CapsoVision (CV) announced that it has submitted an application to the FDA on November 6, requesting breakthrough device designation to accelerate development of the company’s CapsoCam UGI capsule end...
CapsoVision resumed with a Buy at Roth Capital
Roth Capital resumed coverage of CapsoVision (CV) with a Buy rating and $7 price target The firm says the two label expansions in December 2024, to include pediatrics as young
CapsoVision appoints David Garcia as SVP, finance
CapsoVision (CV) announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. He joins CapsoVision after serving as Vice President of Financial Planning a...
CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET
CapsoVision CFO Lundquist steps down
In a regulatory 8-K filing last night, the company stated: “Effective August 27, 2025, Kevin Lundquist has stepped down as Chief Financial Officer of CapsoVision (CV), Inc. The Company has